Registro exitoso
Cuenta activada - Validación pendiente
Su cuenta se ha activado con éxito, pero aún debemos validarlo como profesional de la salud. Le enviaremos un correo electrónico con el resultado del proceso de validación en los próximos cinco días.
Mientras tanto, puede disfrutar del acceso a todas las últimas noticias, eventos y recursos en nuestro sitio web.
240
42 results
Triumeq
Dolutegravir-Abacavir-Lamivudina<br> VIH
Seguridad
Seguridad
Casualidad o elección
Casualidad o elección
Dispositivo
Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.
Dispositivo
Dispositivo
Seguridad
Seguridad
Exacerbaciones
Real-world evidence and clinical trial data reveal how Relvar can reduce the rate of asthma exacerbations vs budesonide/formoterol and ICS, respectively.
Cambiando a Relvar
A patient case study illustrates how Relvar can address invisible symptoms vs patient perceptions of asthma control with ICS/LABA MART regimens.
Monitoreo de la dependencia de SABA
GINA guidelines state that SABA use > twice weekly suggests poor asthma control. Real-world data vs budesonide/formoterol show how Relvar reduces SABA dependence.
EL SLS
Relvar efficacy data from the SLS, which included patients with comorbidities and those who were smokers, who would usually be excluded from RCTs.
Calidad de vida
Post-hoc analysis night-time awakening data from three RCTs and AQLQ data showing how patients with uncontrolled asthma can benefit from taking Relvar.
Efectos en el cortisol y el eje HHS
The maximum licensed dose of Relvar does not affect the HPA axis or significantly suppress cortisol levels.
Índice terapéutico
A video explanation of therapeutic index and how Relvar’s good therapeutic index is linked to the high receptor binding affinity of its constituent molecules.
Control duradero
Data showing that Relvar’s unique formulation provides continuous improvements in lung function and anti-inflammatory effects over the 24-h dosing interval.
Percepción de los pacientes vs. la realidad
Patient case studies showing how patient perceptions of asthma control differ from guideline definitions.
Alcanzando el control del asma
How Relvar can achieve asthma control, using guideline definitions and ACT assessment (includes an external link to the ACT website).
Adherencia
Real-world data showing that Relvar new users were more adherent to, and less likely to discontinue, treatment than new users of other ICS/LABA combinations.
Impacto Ambiental
Published data showing that Relvar has a lower annual carbon footprint and lower lifecycle contributions than many other asthma devices.
Tamaño de la partícula
Relvar’s particle size falls well within the optimal range for absorption, a factor in asthma control that is often overlooked.
Generalidades
Key Relvar benefits in adults/adolescents with uncontrolled, partially controlled or adequately controlled asthma.
Celsentri
Maraviroc <br> VIH
Combivir
Lamivudina-Zidovudina<br> VIH
Seretide en Pediatría
Seretide en Pediatría
Novedades
amoxicillin-clavulanate<br>Anti infectives
Información para prescribir
Información para prescribir
Decodificando Relvar
Relvar Ellipta’s ease of use is shown by a video and by data vs Breezehaler, while its preference by patients vs Turbohaler, Diskus, and MDI is highlighted.
Intercambiabilidad
amoxicillin-clavulanate<br>Anti infectives
Inicio
amoxicillin-clavulanate<br>Anti infectives
Eficacia
amoxicillin-clavulanate<br>Anti infectives
Guías
amoxicillin-clavulanate<br>Anti infectives
Susceptibilidad
amoxicillin-clavulanate<br>Anti infectives
No hubo coincidencias. Intente por favor:
- Revisar la ortografía del término de búsqueda.
- Intente un nuevo término de búsqueda.
- Reestablecer o revisar los filtros de búsqueda (si utilizó filtros para esta búsqueda)
Mostrar más
